|
π
|
An immunogenic personal neoantigen vaccine for patients with melanoma
40 auth.
P. Ott,
Zhuting Hu,
D. Keskin,
S. Shukla,
Jing Sun,
David j. Bozym,
Wandi Zhang,
Adrienne M. Luoma,
A. Giobbie-Hurder,
Lauren Peter,
Christina Chen,
Oriol Olive,
T. Carter,
Shuqiang Li,
David J. Lieb,
...
T. Eisenhaure,
E. Gjini,
Jonathan D. Stevens,
W. Lane,
I. Javeri,
K. Nellaiappan,
A. Salazar,
H. Daley,
Michael G. Seaman,
E. Buchbinder,
Charles H. Yoon,
M. Harden,
N. Lennon,
S. Gabriel,
S. Rodig,
D. Barouch,
J. Aster,
G. Getz,
K. Wucherpfennig,
D. Neuberg,
J. Ritz,
E. Lander,
E. Fritsch,
N. Hacohen,
Catherine J. Wu
|
11 |
2017 |
11
π
|
|
π¦
|
CTLA-4 and PD-1 Pathways
E. Buchbinder,
Anupam M. Desai
|
10 |
2016 |
10
π¦
|
|
π
|
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
21 auth.
Douglas B. Johnson,
R. Sullivan,
P. Ott,
M. Carlino,
N. Khushalani,
Fei Ye,
A. Guminski,
I. Puzanov,
D. Lawrence,
E. Buchbinder,
...
Tejaswi V. Mudigonda,
K. Spencer,
C. Bender,
Jenny H. Lee,
H. Kaufman,
A. Menzies,
J. Hassel,
J. Mehnert,
J. Sosman,
G. Long,
Joseph I. Clark
|
9 |
2016 |
9
π
|
|
π
|
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
54 auth.
Livnat Jerby-Arnon,
Parin Shah,
Michael S. Cuoco,
Christopher Rodman,
Mei-ju Su,
Johannes C. Melms,
Rachel Leeson,
Abhay Kanodia,
Shaolin Mei,
Jia-Ren Lin,
Shu Wang,
Bokang Rabasha,
David Liu,
Gao Zhang,
Claire Margolais,
...
Orr Ashenberg,
P. Ott,
E. Buchbinder,
Rizwan Haq,
F. Hodi,
G. Boland,
Ryan J. Sullivan,
Dennie T. Frederick,
B. Miao,
Tabea Moll,
Keith T. Flaherty,
M. Herlyn,
R. Jenkins,
Rohit Thummalapalli,
Monika S. Kowalczyk,
I. Canadas,
Bastian Schilling,
Adam N. Cartwright,
Adrienne M. Luoma,
Shruti Malu,
P. Hwu,
C. Bernatchez,
M. Forget,
D. Barbie,
A. Shalek,
I. Tirosh,
P. Sorger,
K. Wucherpfennig,
E. Allen,
D. Schadendorf,
B. Johnson,
Asaf Rotem,
Asaf Rotem,
O. Rozenblatt-Rosen,
Levi A. Garraway,
Charles H Yoon,
Charles H Yoon,
B. Izar,
A. Regev
|
8 |
2018 |
8
π
|
|
π
|
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
41 auth.
Zhuting Hu,
Donna E. Leet,
R. AllesΓΈe,
G. Oliveira,
Shuqiang Li,
Adrienne M. Luoma,
Jinyan Liu,
J. Forman,
Teddy Huang,
J. Iorgulescu,
Rebecca L. Holden,
Siranush Sarkizova,
S. Gohil,
R. Redd,
Jing Sun,
...
Liudmila Elagina,
A. Giobbie-Hurder,
Wandi Zhang,
Lauren Peter,
Zoe B. Ciantra,
S. Rodig,
Oriol Olive,
K. Shetty,
Jason W Pyrdol,
Mohamed Uduman,
Patrick C. Lee,
P. Bachireddy,
E. Buchbinder,
Charles H. Yoon,
D. Neuberg,
B. Pentelute,
N. Hacohen,
K. Livak,
S. Shukla,
L. Olsen,
D. Barouch,
K. Wucherpfennig,
E. Fritsch,
D. Keskin,
Catherine J. Wu,
P. Ott
|
8 |
2021 |
8
π
|
|
π
|
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
53 auth.
S. Patel,
M. Othus,
Yuanbin Chen,
G. Wright,
K. Yost,
John R Hyngstrom,
S. Hu-Lieskovan,
C. Lao,
L. Fecher,
T. Truong,
Jennifer Eisenstein,
S. Chandra,
J. A. Sosman,
K. Kendra,
Richard C Wu,
...
C. Devoe,
G. Deutsch,
A. Hegde,
M. Khalil,
A. Mangla,
A. Reese,
M. Ross,
A. Poklepovic,
G. Phan,
A. Onitilo,
Demet YaΕar,
Benjamin Powers,
G. Doolittle,
G. In,
Niels Kokot,
G. Gibney,
M. Atkins,
M. Shaheen,
J. Warneke,
A. Ikeguchi,
J. E. Najera,
B. Chmielowski,
J. Crompton,
J. Floyd,
E. Hsueh,
K. Margolin,
W. Chow,
K. Grossmann,
E. Dietrich,
V. Prieto,
M. Lowe,
E. Buchbinder,
John M. Kirkwood,
L. Korde,
J. Moon,
E. Sharon,
V. Sondak,
A. Ribas
|
8 |
2023 |
8
π
|
|
π
|
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
27 auth.
R. Sullivan,
J. Infante,
F. Janku,
D. Wong,
J. Sosman,
V. Keedy,
M. Patel,
G. Shapiro,
J. Mier,
A. Tolcher,
A. Wang-Gillam,
M. Sznol,
K. Flaherty,
E. Buchbinder,
R. Carvajal,
...
A. Varghese,
M. Lacouture,
A. Ribas,
S. Patel,
G. Decrescenzo,
Caroline M. Emery,
A. Groover,
Saurabh Saha,
M. Varterasian,
D. Welsch,
D. Hyman,
Bob T. Li
|
8 |
2017 |
8
π
|
|
π
|
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
18 auth.
J. Weber,
G. Gibney,
R. Sullivan,
J. Sosman,
C. Slingluff,
D. Lawrence,
T. Logan,
L. Schuchter,
S. Nair,
L. Fecher,
...
L. Fecher,
E. Buchbinder,
E. Berghorn,
Mary M. Ruisi,
G. Kong,
Joel Jiang,
C. Horak,
F. Hodi
|
8 |
2016 |
8
π
|
|
π’
|
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
Louis M. Weiner,
Soldano Ferrone,
P. Ott,
F. Stephen Hodi,
E. Buchbinder
|
7 |
2015 |
7
π’
|
|
π
|
Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.
11 auth.
A. Mahadevan,
R. Miksad,
M. Goldstein,
R. Sullivan,
A. Bullock,
E. Buchbinder,
...
D. Pleskow,
M. Sawhney,
T. Kent,
C. Vollmer,
M. Callery
|
7 |
2011 |
7
π
|
|
π¦
|
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
E. Buchbinder,
F. Hodi,
Pfizer Bristol-Myers Squibb Merck
|
7 |
2015 |
7
π¦
|
|
π
|
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factorβbearing microparticles: a randomizedβcontrolled phase II trial (the Microtec study)
15 auth.
J. Zwicker,
H. Liebman,
K. Bauer,
Thomas Caughey,
F. Campigotto,
R. Rosovsky,
S. Mantha,
C. Kessler,
J. Eneman,
V. Raghavan,
...
H. Lenz,
A. Bullock,
E. Buchbinder,
D. Neuberg,
B. Furie
|
7 |
2013 |
7
π
|
